Samer Al'Hadidi, MD, discusses monitoring strategies for patients with relapsed/refractory multiple myeloma who are receiving lenalidomide.
Relapsed/Refractory Multiple Myeloma Algorithm
An expert on the treatment of multiple myeloma discusses the role of CAR T-cell therapy in relapsed/refractory disease.
In a discussion with the Oncology Brothers on the treatment of patients with relapsed/refractory multiple myeloma, Samer Al'Hadidi, MD, discusses adverse effects associated with CAR T-cell therapy and bispecific antibodies.
Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Samer Al'Hadidi, MD, to discuss treatment decision-making strategies for patients with relapsed/refractory multiple myeloma.
Samer Al'Hadidi, MD, offers advice to community oncologists who treat patients with relapsed/refractory multiple myeloma, and the Oncology Brothers recap the entire discussion.
Advertisement
Advertisement
Trending on CancerNetwork
1
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
2
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
3
Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs
4
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
5
